These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2180212)

  • 21. [Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
    Fiegel G
    Med Welt; 1982 Mar; 33(9):334-6. PubMed ID: 7045566
    [No Abstract]   [Full Text] [Related]  

  • 22. [Drug therapy of dyslipidemias].
    Fonda M; Cattin L; Guarnieri G
    Recenti Prog Med; 2000; 91(7-8):375-8. PubMed ID: 10932924
    [No Abstract]   [Full Text] [Related]  

  • 23. [Changes in parameters of lipid metabolism and anti-oxidative potentials in elderly hyperlipoproteinemic patients treated with omega-3 fatty acids].
    Reuter W; Vorberg B; Sauer I; Krumpolt C
    Z Gerontol; 1994; 27(3):204-7. PubMed ID: 8091840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs].
    Jacobsson L
    Z Gesamte Inn Med; 1986 Jul; 41(14):387-91. PubMed ID: 3532591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacologic therapy of hyperlipoproteinemia and its pitfalls].
    Ceska R
    Vnitr Lek; 1993 Feb; 39(2):191-7. PubMed ID: 8506668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug therapy for dyslipoproteinaemia.
    Bain SC; Barnett AH; Jones AF
    Diabet Med; 1990 Dec; 7(10):931-4. PubMed ID: 2149695
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia.
    Weisweiler P
    Arzneimittelforschung; 1988 Jul; 38(7):925-7. PubMed ID: 3207437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of the effects of tiadenol in various types of dyslipidemia].
    Saettone G; Cazzani E; Romanò M; Muzio L
    Clin Ter; 1982 May; 101(4):387-93. PubMed ID: 7105643
    [No Abstract]   [Full Text] [Related]  

  • 29. [Dyslipoproteinemia in elderly patients].
    Bláha V; Solichová D; Zadák Z
    Vnitr Lek; 2000 Sep; 46(9):551-4. PubMed ID: 11344651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mixed dyslipoproteinemias: new therapeutic opportunities].
    Capurso A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():44S-47S. PubMed ID: 8562265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB; Donega P; Passaro A; Zanca R; Cattin L; Fonda M; Pauciullo P; Marotta G; Fellin R; Gasparrini S; Piliego T
    Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lipid metabolism in man--new knowledge on molecular level gives hope for better therapy].
    Angelin B; Rudling M
    Lakartidningen; 1991 May; 88(18):1681-6. PubMed ID: 1674974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
    Ceska R; Sobra J; Procházková R; Kvasilová M
    Vnitr Lek; 1990 Apr; 36(4):363-7. PubMed ID: 2356612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
    Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
    Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacotherapy of hyperlipoproteinemia].
    Soska V
    Vnitr Lek; 2000 Sep; 46(9):565-8. PubMed ID: 11344654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The primary hyperlipoproteinemias.
    Bybee DE; Hamilton RD
    J Ky Med Assoc; 1974 Dec; 72(12):658-62. PubMed ID: 4373515
    [No Abstract]   [Full Text] [Related]  

  • 38. [The status quo of pharmacotherapy of lipid metabolism disorders in the aged].
    Reuter VW
    Z Alternsforsch; 1988; 43(1):43-6. PubMed ID: 3281379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
    Levy RI; Troendle AJ; Fattu JM
    Circulation; 1993 Apr; 87(4 Suppl):III45-53. PubMed ID: 8462180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.